Subunit vaccination benefits from improved safety over attenuated or inactivated vaccines,
but their limited capability to elicit long-lasting, concerted cellular and humoral immune …

Leishmaniasis continues to pose a major public health problem worldwide. With new
epidemics occurring in endemic areas and the spread of the disease to previously free …

In the design of vaccine generation, significant attempts have been made to produce novel
vaccines and, as well, to increase the effectiveness of available vaccines versus particular …

The solid lipid nanoparticles (SLNs) usually consists of active drug molecules along with
solid lipids, surfactants, and/or co-surfactants. They possess some potential features such as …

Leishmaniasis is a widely distributed protozoan vector-born disease affecting almost 350
million people. Initially, chemotherapeutic drugs were employed for leishmania treatment but …

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have been
recognized, among the large number of non-viral vectors for gene transfection, as an …

Leishmaniasis remains a public health problem worldwide, affecting approximately 12
million people in 88 countries; 50 000 die of it each year. The disease is caused by …

Legumain-based DNA vaccines have potential to protect against breast cancer. However,
the lack of a safe and efficient oral delivery system restricts its clinical application. Here, we …

DNA vaccination has emerged as a promising alternative to traditional protein-based
vaccines for the induction of protective immune responses. DNA vaccines offer several …

Mucosal sites serve as the main portal for the entry of pathogens and thus immunization
through mucosal routes can greatly improve the immunity. Researchers are continuously …